Last reviewed · How we verify
NCT07309588
Hyaluronic Acid in the Treatment of Hyposalivation
Phase 1, PHASE2 trial testing Sunecos-200 Injectable Hyaluronic acid and amino acids solution in Xerostomia Due to Hyposecretion of Salivary Gland in 100 participants. Enrolling by invitation.
19 December 2025
Quick facts
| Lead sponsor | Poznan University of Medical Sciences |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 July 2025 |
| Primary completion | 19 December 2025 |
| Estimated completion | 19 January 2026 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Sunecos-200 Injectable Hyaluronic acid and amino acids solution
Conditions studied
- Xerostomia Due to Hyposecretion of Salivary Gland — all drugs for Xerostomia Due to Hyposecretion of Salivary Gland →
Sponsor
Poznan University of Medical Sciences
Who can join
Adults 38 to 78, any sex, with Xerostomia Due to Hyposecretion of Salivary Gland. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if drug containing non-crosslinked hyaluronic acid and amino acids solution (Sunecos-200) works to treat hyposalivation in adults. It will also learn about the safety of drug Sunecos-200. The main questions it aims to answer are: * Does Sunecos-200 improve the saliva secretion and improve a life comfort? * What medical problems do participants have when taking Sunecos-200? Researchers will compare drug containing non-crosslinked hyaluronic acid and amino acids solution (Sunecos-200) to a control group (without intervention) to see if drug Sunecos-200 works to treat hyposalivation. Participants will: * Take drug Sunecos-200 by into oral mucosa injection or nothing every two weeks for 4 times. * Visit the clinic once every 2 weeks for checkups and tests * Keep a diary of their symptoms after injection and fill out a primary and final questionary.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07309588
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Poznan University of Medical Sciences trials
Trials by the same sponsor.
- NCT07449468 — PENG Block and Delirium After Hip Arthroplasty · NA · not yet recruiting
- NCT07449442 — SII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty · NA · not yet recruiting
- NCT07474896 — Diaphragm-Sparing Regional Anesthesia Techniques for Shoulder Surgery · NA · not yet recruiting
- NCT07474909 — Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery · NA · not yet recruiting
- NCT07449403 — SII Levels Following PENG Block in Hip Arthroplasty · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07309588 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Poznan University of Medical Sciences
- Last refreshed: 30 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07309588.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing